scholarly journals Cutaneous Melanoma, Hodgkin's Lymphoma and non-Hodgkin's Lymphoma: Common Risk Factors?

2015 ◽  
Vol 23 (2) ◽  
pp. 119-121
Keyword(s):  
Risk Factors ◽  
Cutaneous Melanoma ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Common Risk Factors

Agricultural risk factors for t(14;18) subtypes of non-Hodgkin’s lymphoma

Epidemiology ◽  
2001 ◽  
Vol 12 (6) ◽  
pp. 701-709 ◽  
Author(s):  
Jane C. Schroeder ◽  
Andrew F. Olshan ◽  
Ralph Baric ◽  
Georgette A. Dent ◽  
Clarice R. Weinberg ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Agricultural Risk ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Re: Medical History Risk Factors for Non-Hodgkin's Lymphoma in Older Women

1997 ◽  
Vol 89 (11) ◽  
pp. 816-817 ◽  
Author(s):  
E. Weiderpass ◽  
O. Nyren ◽  
A. Ekbom ◽  
H.-O. Adami ◽  
G. Gridley ◽  
...  
Keyword(s):  
Risk Factors ◽  
Medical History ◽  
Older Women ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Risk Factors for Venous Thromboembolism (VTE) among Patients with Active Hematological Cancer: A Population-Based Case-Control Study.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1642-1642
Author(s):  
Aneel A. Ashrani ◽  
John A. Heit ◽  
Jeffrey A. Schmoll ◽  
Sara A. Farmer ◽  
Tanya M. Petterson ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Leukemia ◽  
Cancer Patients ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Cancer Type ◽  
Hematological Cancer ◽  
Stage Progression ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract Background: Hematological cancer patients are at an increased risk for VTE (RR range = 12–32). However, whether VTE risk among such patients can be further stratified is uncertain. Objective: To test hematological cancer type, stage, stage progression and chemotherapy as potential risk factors for VTE among active hematological cancer patients after controlling for other previously-identified VTE risk factors. Methods: Using the resources of the Rochester Epidemiology Project, Mayo Clinic Master Diagnostic Index and Mayo Clinic Tumor Registry, we identified all Olmsted County, MN residents with active hematological cancer over the 28-year period, 1973–2000. From this prevalence cohort, we identified 86 patients with no prior VTE (controls) who were matched on age and date of hematological cancer diagnosis to 86 hematological cancer patients with incident VTE over the same time frame (cases). For all cases and controls, we reviewed the complete medical records in the community for baseline and hematological cancer-related characteristics. Hematological cancers were re-staged at the dates of the cancer and VTE diagnosis. We tested these characteristics as potential risk factors for VTE in active hematological cancer using conditional logistic regression. Results: In an initial multivariate analysis that included body mass index (BMI), hospitalization, and any infection or central venous catheter placement within 90 days prior to the VTE event, VTE was significantly associated with hospitalization (OR=6.70; p<0.001), and marginally associated with any infection (OR=2.18; p=0.09). After adjusting for the above variables, chemotherapy administered within the preceding 90 days was significantly associated with VTE (OR=4.25; p=0.02), while stage progression was marginally associated (OR=4.79; p=0.10). Compared to all other hematological cancer types, acute leukemia (OR=5.95; p=0.01) and non-Hodgkin’s lymphoma (OR=2.61; p=0.01) were associated with VTE. However, after adjusting for BMI, hospitalization, any infection and central venous catheter, only non-Hodgkin’s lymphoma was independently associated with VTE (OR=3.79, p=0.009), while acute leukemia was not (OR=2.66, p=0.35). Conclusions: Hematological cancer type (in particular, non-Hodgkin’s lymphoma and possibly acute leukemia), recent hospitalization, recent chemotherapy, and possibly stage progression and recent infection, are risk factors for VTE among patients with active hematological cancer.

Doxorubicin, Cardiac Risk Factors, and Cardiac Toxicity in Elderly Patients With Diffuse B-Cell Non-Hodgkin's Lymphoma

2008 ◽  
Vol 26 (19) ◽  
pp. 3159-3165 ◽  
Author(s):  
Dawn L. Hershman ◽  
Russell B. McBride ◽  
Andrew Eisenberger ◽  
Wei Yann Tsai ◽  
Victor R. Grann ◽  
...  
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Elderly Patients ◽  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Cardiac Risk ◽  
Hodgkin's Lymphoma ◽  
Cardiac Risk Factors ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Purpose Anthracycline-based chemotherapy, which improves survival for patients with non-Hodgkin's lymphoma, is often withheld from elderly patients because of its cardiotoxicity. We studied the cardiac effects of doxorubicin in a population-based sample of older patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods Among patients age ≥ 65 years diagnosed with DLBCL from 1991 to 2002 in the Surveillance, Epidemiology, and End Results–Medicare database, we developed logistic regression models of the associations of doxorubicin with demographic, clinical, and cardiac variables. We then developed Cox proportional hazards models of the association between doxorubicin and subsequent congestive heart failure (CHF), taking predictors of CHF into account. Results Of 9,438 patients with DLBCL, 3,164 (42%) received doxorubicin-based chemotherapy. Any doxorubicin use was associated with a 29% increase in risk of CHF (95% CI, 1.02 to 1.62); CHF risk increased with number of doxorubicin claims, increasing age, prior heart disease, comorbidities, diabetes, and hypertension; hypertension intensified the effect of doxorubicin on risk of CHF (hazard ratio = 1.8; P < .01). In the 8 years after diagnosis, the adjusted CHF-free survival rate was 74% in doxorubicin-treated patients versus 79% in patients not treated with doxorubicin. Conclusion Among patients receiving chemotherapy for DLBCL, those with prior heart disease were less likely than others to be treated with doxorubicin, and those who received doxorubicin were more likely than others to develop CHF. Various cardiac risk factors increased CHF risk, but only hypertension was synergistic with doxorubicin. Doxorubicin has dramatically improved survival of DLBCL patients; nonetheless, some subgroups may benefit from efforts to reduce doxorubicin-related CHF risk.

scholarly journals Ocular adnexal non-Hodgkin’s lymphoma: a review of epidemiology and risk factors

2011 ◽  
Vol 6 (2) ◽  
pp. 181-193 ◽  
Author(s):  
Roxana Moslehi ◽  
Maria J Schymura ◽  
Seema Nayak ◽  
F Bruce Coles
Keyword(s):  
Risk Factors ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma
Sign in / Sign up

Export Citation Format

Share Document